CHECKIT
John Wilson
CEO
We have worked with Yellowstone Advisory for a number of years and they transformed our investor relations strategy which significantly increased the interest of our business to both institutional and retail investors. We have been impressed by their understanding of the smaller companies market and their results focussed approach to IR. I would recommend their services without hesitation.
EQUINITI
Guy Wakeley
CEO
Yellowstone Advisory provided valuable input into the interim results announcement and presentation, helping to ensure the investment messaging was consistent throughout the documents. Great relationships and credibility with investors enables them to solicit useful feedback which we have used in developing our future investor messaging.
.png)
Wed, 20 May
|Oxford Biodynamics Webinar
Oxford Biodynamics Webinar
Christian Hoyer Millar, Director and co-founder at Oxford Biodynamics provides an introduction to the company and updates on recent events
Time & Location
20 May 2020, 12:30
Oxford Biodynamics Webinar
About the event
Christian Hoyer Millar, Director and co-founder at Oxford Biodynamics provides an introduction to the company and updates on recent events.
Christian read PPE at Lincoln College, Oxford. His career started in consulting before moving Hoogovens/Hoechst as a director of two of their subsidiaries in the UK, winning the Queen’s award for Exports in one of those subsidiaries. He then worked in both investment banking and venture capital, initially with Ensign Trust Plc.
Christian founded Oxford BioDynamics in 2007 with Dr. Alexandre Akoulitchev and Dr. Aroul Ramadass. Christian was the Chairman of both Chronos Therapeutics Limited and Sibelius Limited until August 2016, at which point he stepped down from both roles although remains as a non-executive director.
Company Description: Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.